+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID05512364

Phase III Trial Comparing Oral Elacestrant to Standard Endocrine Therapy in ER-positive, HER2-negative Breast Cancer Patients With ctDNA Relapse

Led by European Organisation for Research and Treatment of Cancer - EORTC · Updated on 2026-10-07

220

Participants Needed

113

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting an international, multi-center, randomized, open-label phase III trial to compare elacestrant with standard endocrine therapy in patients with ER-positive, HER2-negative breast cancer who have relapse detected by circulating tumor DNA ctDNA. The study focuses on patients who show ctDNA in their blood but have no distant metastasis, aiming to evaluate treatment outcomes and disease progression. This trial involves a screening phase to monitor ctDNA presence and a randomized treatment phase for eligible patients. During the ctDNA screening phase, patients receive standard adjuvant endocrine therapy, such as tamoxifen or aromatase inhibitors, and undergo plasma testing every six months for up to approximately 5.7 years. Patients who test ctDNA-positive undergo imaging to rule out metastasis and, if eligible, are randomized within four weeks to either continue their current endocrine treatment or receive elacestrant at 400 mg daily orally. Treatment duration varies based on prior endocrine therapy length, lasting between 2 and 7 years. Follow-up includes frequent ctDNA testing and imaging over three years to monitor disease status. Participants will have plasma samples collected regularly during screening and follow-up. Imaging assessments such as mammograms, bone scans, and CT scans are performed to detect metastases or recurrences. Researchers will track distant metastasis-free survival and other outcomes including overall survival, disease recurrence, adverse events, and quality of life over extended periods, up to 11.7 years. The study ensures ongoing monitoring and safety evaluations throughout treatment and follow-up until study completion.

CONDITIONS

Brief Title

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

Research Team

E

EORTC HQ

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here